Healthcare provider profile · identity verified

Phu Tien Vu, MD

Family Practice · MANTECA, CA · NPI 1306924204

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	422	182
Amlodipine Besylate	Amlodipine Besylate	229	97
Lisinopril	Lisinopril	217	96
Levothyroxine Sodium	Levothyroxine Sodium	198	71
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	172	65
Losartan Potassium	Losartan Potassium	162	66
Metformin Hcl	Metformin Hcl	156	68
Ibuprofen	Ibuprofen	141	57
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	132	44
Gabapentin	Gabapentin	117	47
Tamsulosin Hcl	Tamsulosin Hcl	108	50
Fluticasone Propionate	Fluticasone Propionate	107	48
Famotidine	Famotidine	105	46
Simvastatin	Simvastatin	97	39
Albuterol Sulfate Hfa	Albuterol Sulfate	95	57
Metoprolol Tartrate	Metoprolol Tartrate	88	38
Ozempic	Semaglutide	87	18
Metoprolol Succinate	Metoprolol Succinate	81	29
Glipizide	Glipizide	78	34
Atenolol	Atenolol	74	34
Metformin Hcl Er	Metformin Hcl	57	23
Omeprazole	Omeprazole	56	27
Alendronate Sodium	Alendronate Sodium	53	23
Clopidogrel	Clopidogrel Bisulfate	53	23
Baclofen	Baclofen	51	20
Hydrochlorothiazide	Hydrochlorothiazide	51	24
Pantoprazole Sodium	Pantoprazole Sodium	51	21
Alvesco	Ciclesonide	46	20
Montelukast Sodium	Montelukast Sodium	44	16
Terazosin Hcl	Terazosin Hcl	44	17
Trazodone Hcl	Trazodone Hcl	43	21
Finasteride	Finasteride	41	15
Furosemide	Furosemide	40	23
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	39	39
Jardiance	Empagliflozin	36	15
Carvedilol	Carvedilol	34	14
Triamcinolone Acetonide	Triamcinolone Acetonide	34	15
Lovastatin	Lovastatin	32	13
Humulin N	Insulin Nph Human Isophane	27	13
Hydralazine Hcl	Hydralazine Hcl	27	17
Allopurinol	Allopurinol	26	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	19
Tramadol Hcl	Tramadol Hcl	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	22	suppressed
Cephalexin	Cephalexin	22	20
Acyclovir	Acyclovir	21	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	21	11
Colchicine	Colchicine	20	11
Spiriva Respimat	Tiotropium Bromide	20	suppressed
Meloxicam	Meloxicam	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	18	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	18	suppressed
Pregabalin	Pregabalin	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Sucralfate	Sucralfate	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	13
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	15	suppressed
Ondansetron Odt	Ondansetron	15	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Temazepam	Temazepam	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Glipizide Er	Glipizide	13	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	13	suppressed
Humulin R	Insulin Regular, Human	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Sertraline Hcl	Sertraline Hcl	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Nabumetone	Nabumetone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error